Stock:
Symbol Lookup
Register | Login
...
History
...
...

Pre Market | Dow Jones | Gold | Newsletters | Learn


OPKO Health - OPK - To acquire Cytochroma Inc.

Wednesday, January 9, 2013 11:47 AM
OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. Replidea™ has been shown in a phase 2b clinical trial to effectively and safely treat SHPT and the underlying vitamin D insufficiency in pre-dialysis patients. Vitamin D insufficiency arises in CKD due to the abnormal upregulation of CYP24, an enzyme which destroys vitamin D and its metabolites. Studies in CKD patients have demonstrated that currently available over-the-counter and prescription vitamin D products cannot reliably raise blood vitamin D prohormone levels or effectively treat SHPT. "OPKO intends to market Replidea™ along with our proprietary point-of-care vitamin D diagnostic test currently in development," stated Phillip Frost, MD, CEO and Chairman. "We envision these remarkable products as part of the foundation for a new and markedly improved standard of care for chronic kidney disease patients having SHPT and/or hyperphosphatemia." Alpharen™ has been shown safe and effective in treating hyperphosphatemia in the phase 2 and 3 clinical trials undertaken to date in dialysis patients. Hyperphosphatemia (elevated serum phosphorus) exacerbates SHPT and promotes bone disease, soft tissue mineralization and progression of kidney disease. Approximately 90% of dialysis patients in the United States require regular treatment. Cytochroma's officers, including Charles W. Bishop, PhD, CEO, an authority on developing and commercializing successful new vitamin D therapies, and Eric J. Messner, MBA, having a noteworthy track record in pharmaceutical business development and in marketing and sales in the CKD arena, will join the OPKO management team. Prior to Cytochroma, Dr. Bishop and Mr. Messner held key positions at Bone Care International, Inc., a leader in vitamin D therapeutics acquired by Genzyme Corporation, now a division of Sanofi. About Cytochroma Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD.  About OPKO Health, Inc. - OPK OPKO (OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
PRINT

FREE Options Trading Lessons
I'll show you how to unlock HUGE Gains with Options Trading
Let's make 2015 the year you get RICH!

Latest Headlines

Altice seeks financing for Time Warner Cable bid: sourcesAltice seeks financing for Time Warner Cable bid: sources
SAN FRANCISCO/LONDON (Reuters) - French telecommunications group Altice SA is in talks with several banks about raising debt for a bid for Time Warner Cable Inc, the second-largest U.S. cable operat...
Exclusive: Altice seeks financing for Time Warner Cable bid: sourcesExclusive: Altice seeks financing for Time Warner Cable bid: sources
SAN FRANCISCO/LONDON (Reuters) - French telecommunications group Altice SA is talking to several banks about raising debt for a potential bid for Time Warner Cable Inc, the second-largest U.S. cable...
Exclusive: Altice seeks financing for Time Warner Cable bid: sourcesExclusive: Altice seeks financing for Time Warner Cable bid: sources
(Reuters) - French telecommunications group Altice SA is in talks with several banks about raising debt for a bid for Time Warner Cable Inc, the second-largest U.S. cable operator, according to people...
Will Apple Deploy Robot-Led Indoor Mapping?Will Apple Deploy Robot-Led Indoor Mapping?
9to5 Mac, a popular blog that covers Apple Inc. (NASDAQ: AAPL ) news and rumors reported on Thursday that the company is making headway on its indoor mapping project. According to 9to5 Mac, App...
U.S.-focused stock funds worldwide post $8.5 bln outflows in week-BofAU.S.-focused stock funds worldwide post $8.5 bln outflows in week-BofA
(Reuters) - Investors worldwide pulled $8.5 billion out of funds that specialize in U.S. stocks in the week ended May 20, data from a Bank of America Merrill Lynch Global Research report showed on Fri...

Loading Headlines...
 

Stock Market

Track the stock market today with the latest news and information on all things investing! Watch your stocks perform throughout the day and watch the breaking stock market news.

Feedback | disclaimer | privacy policy

Stock Market News

The Stock Market is ever changing. Keep up on your stock market news.

Stock Market Newsletters

Read up on your favorite stock market newsletters.


Learn the Stock Market

Sharper your stock trading skills with our stock market education section.

Algorithm Based
Trade Signals
arrow
swing trades FREE Swing Trade Ideas Clear, simple swing trades.
small cap swing trades Futures Day Trading System S&P + Crude Oil Signals
Autotrading Autotrade Stocks Try for Free!